189 related articles for article (PubMed ID: 24747613)
1. Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson's disease.
Shin KS; Zhao TT; Choi HS; Hwang BY; Lee CK; Lee MK
Brain Res; 2014 Jun; 1567():57-65. PubMed ID: 24747613
[TBL] [Abstract][Full Text] [Related]
2. Gypenosides attenuate the development of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Zhao TT; Park KH; Park HJ; Hwang BY; Lee CK; Lee MK
BMC Neurosci; 2015 Apr; 16():23. PubMed ID: 25896846
[TBL] [Abstract][Full Text] [Related]
3. Gynostemma pentaphyllum Ethanolic Extract Protects Against Memory Deficits in an MPTP-Lesioned Mouse Model of Parkinson's Disease Treated with L-DOPA.
Kim KS; Zhao TT; Shin KS; Park HJ; Cho YJ; Lee KE; Kim SH; Lee MK
J Med Food; 2017 Jan; 20(1):11-18. PubMed ID: 28005447
[TBL] [Abstract][Full Text] [Related]
4. Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
Zhao TT; Kim KS; Shin KS; Park HJ; Kim HJ; Lee KE; Lee MK
BMC Complement Altern Med; 2017 Sep; 17(1):449. PubMed ID: 28877690
[TBL] [Abstract][Full Text] [Related]
5. Ameliorating effects of gypenosides on chronic stress-induced anxiety disorders in mice.
Zhao TT; Shin KS; Choi HS; Lee MK
BMC Complement Altern Med; 2015 Sep; 15():323. PubMed ID: 26370834
[TBL] [Abstract][Full Text] [Related]
6. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
[TBL] [Abstract][Full Text] [Related]
7. Anxiolytic effects of herbal ethanol extract from Gynostemma pentaphyllum in mice after exposure to chronic stress.
Choi HS; Zhao TT; Shin KS; Kim SH; Hwang BY; Lee CK; Lee MK
Molecules; 2013 Apr; 18(4):4342-56. PubMed ID: 23584055
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
9. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective effect of gypenosides against oxidative injury in the substantia nigra of a mouse model of Parkinson's disease.
Wang P; Niu L; Gao L; Li WX; Jia D; Wang XL; Gao GD
J Int Med Res; 2010; 38(3):1084-92. PubMed ID: 20819446
[TBL] [Abstract][Full Text] [Related]
11. Ropinirole protects against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-induced neurotoxicity in mice via anti-apoptotic mechanism.
Park G; Park YJ; Yang HO; Oh MS
Pharmacol Biochem Behav; 2013 Mar; 104():163-8. PubMed ID: 23369986
[TBL] [Abstract][Full Text] [Related]
12. A30P α-synuclein impairs dopaminergic fiber regeneration and interacts with L-DOPA replacement in MPTP-treated mice.
Szego ÉM; Gerhardt E; Kermer P; Schulz JB
Neurobiol Dis; 2012 Jan; 45(1):591-600. PubMed ID: 22001606
[TBL] [Abstract][Full Text] [Related]
13. Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.
Riahi G; Morissette M; Parent M; Di Paolo T
Eur J Neurosci; 2011 May; 33(10):1823-31. PubMed ID: 21501255
[TBL] [Abstract][Full Text] [Related]
14. Effects of ceftriaxone on the behavioral and neuronal changes in an MPTP-induced Parkinson's disease rat model.
Ho SC; Hsu CC; Pawlak CR; Tikhonova MA; Lai TJ; Amstislavskaya TG; Ho YJ
Behav Brain Res; 2014 Jul; 268():177-84. PubMed ID: 24755306
[TBL] [Abstract][Full Text] [Related]
15. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
[TBL] [Abstract][Full Text] [Related]
16. L-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease.
Huot P; Johnston TH; Koprich JB; Fox SH; Brotchie JM
Neuropharmacology; 2012 Oct; 63(5):829-36. PubMed ID: 22722022
[TBL] [Abstract][Full Text] [Related]
17. Ethanol extract from
Park HJ; Zhao TT; Kim SH; Lee CK; Hwang BY; Lee KE; Lee MK
Neural Regen Res; 2020 Feb; 15(2):361-368. PubMed ID: 31552910
[TBL] [Abstract][Full Text] [Related]
18. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
Yabuki Y; Ohizumi Y; Yokosuka A; Mimaki Y; Fukunaga K
Neuroscience; 2014 Feb; 259():126-41. PubMed ID: 24316474
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective effects of (+/-)-kavain in the MPTP mouse model of Parkinson's disease.
Schmidt N; Ferger B
Synapse; 2001 Apr; 40(1):47-54. PubMed ID: 11170221
[TBL] [Abstract][Full Text] [Related]
20. The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.
Lazzara CA; Riley RR; Rane A; Andersen JK; Kim YH
Brain Res; 2015 Oct; 1622():127-36. PubMed ID: 26119916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
